Follistatin Gene Delivery Enhances Muscle Growth and Strength in Nonhuman Primates
- 11 November 2009
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 1 (6), 6ra15
- https://doi.org/10.1126/scitranslmed.3000112
Abstract
Antagonists of myostatin, a blood-borne negative regulator of muscle growth produced in muscle cells, have shown considerable promise for enhancing muscle mass and strength in rodent studies and could serve as potential therapeutic agents for human muscle diseases. One of the most potent of these agents, follistatin, is both safe and effective in mice, but similar tests have not been performed in nonhuman primates. To assess this important criterion for clinical translation, we tested an alternatively spliced form of human follistatin that affects skeletal muscle but that has only minimal effects on nonmuscle cells. When injected into the quadriceps of cynomolgus macaque monkeys, a follistatin isoform expressed from an adeno-associated virus serotype 1 vector, AAV1-FS344, induced pronounced and durable increases in muscle size and strength. Long-term expression of the transgene did not produce any abnormal changes in the morphology or function of key organs, indicating the safety of gene delivery by intramuscular injection of an AAV1 vector. Our results, together with the findings in mice, suggest that therapy with AAV1-FS344 may improve muscle mass and function in patients with certain degenerative muscle disorders.This publication has 47 references indexed in Scilit:
- Limb‐girdle muscular dystrophy type 2D gene therapy restores α‐sarcoglycan and associated proteinsAnnals of Neurology, 2009
- Inhibition of myostatin with emphasis on follistatin as a therapy for muscle diseaseMuscle & Nerve, 2009
- Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytesNature Biotechnology, 2008
- Facioscapulohumeral muscular dystrophyNeurotherapeutics, 2008
- Long-term enhancement of skeletal muscle mass and strength by single gene administration of myostatin inhibitorsProceedings of the National Academy of Sciences of the United States of America, 2008
- Quadrupling Muscle Mass in Mice by Targeting TGF-ß Signaling PathwaysPLOS ONE, 2007
- Lack of myostatin results in excessive muscle growth but impaired force generationProceedings of the National Academy of Sciences of the United States of America, 2007
- The Heparin Binding Site of Follistatin Is Involved in Its Interaction with ActivinBiochemical and Biophysical Research Communications, 1995
- Randomized, Double-Blind Six-Month Trial of Prednisone in Duchenne's Muscular DystrophyThe New England Journal of Medicine, 1989
- Porcine follistatin gene structure supports two forms of mature follistatin produced by alternative splicingBiochemical and Biophysical Research Communications, 1988